Mirati Therapeutics
Jun 1, 2016

Mirati Therapeutics To Present At The Jefferies 2016 Healthcare Conference

SAN DIEGO, June 1, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 11:00 a.m. ET (8:00 a.m. PT) in New York.

A live audio webcast of the presentation will be accessible on the "Investors" page of Mirati's corporate website at www.mirati.com. A replay of the presentation will be available at the same location for 60 days following the conference.

About Mirati Therapeutics
Mirati Therapeutics develops molecularly targeted therapies intended to treat cancer by combining the three most important factors in oncology drug development: 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer as single agents and in combination, including combination with immune therapy, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. The Mirati team uses a blueprint proven by their prior work for developing potential breakthrough cancer therapies with accelerated development paths to improve outcomes for patients. Mirati is advancing three drug candidates through clinical development for multiple oncology indications. More information is available at www.mirati.com.

Logo

Logo - http://photos.prnewswire.com/prnh/20160307/341355LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-at-the-jefferies-2016-healthcare-conference-300277523.html

SOURCE Mirati Therapeutics, Inc.

News Provided by Acquire Media